Melissa E Murray, PhD, Mayo Clinic, Jacksonville, FL, discusses highlights from the AD/PD 2024 forum regarding the future of blood-based biomarker regulation and community care. Improved access to care through fluid biomarkers is promising. However, it is necessary to have highly accurate biomarkers to prevent overinterpretation by healthcare providers in non-specialized settings. The combination of fluid biomarkers, helping with early disease detection, and neuroimaging, enhancing understanding of advanced neuronal damage, could be very useful. Attention is also drawn to the need for accurate combinations of biomarkers for predictive purposes. This interview took place at the AP/PD™ 2024 congress in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть